Sir James Whyte Black (14 June 1924 – 22 March 2010) was a Scottish physician and pharmacologist. Together with Gertrude B. Elion and George H. Hitchings, he shared the Nobel Prize for Medicine in 1988 for pioneering strategies for rational drug-design, which, in his case, led to the development of propranolol and cimetidine. Black established a Veterinary Physiology department at the University of Glasgow, where he became interested in the effects of adrenaline on the human heart. He went to work for ICI Pharmaceuticals in 1958 and, while there, developed propranolol, a beta blocker used for the treatment of heart disease. Black was also responsible for the development of cimetidine, an H2 receptor antagonist, a drug used to treat stomach ulcers.
Early life and education Black was born on 14 June 1924 in Uddingston, Lanarkshire, the fourth of five sons of a Baptist family which traced its origins to Balquhidder, Perthshire. His father Walter Black was a mining engineer and his mother was Catherine Reid Whyte. He was brought up in Fife, educated at Beath High School, Cowdenbeath, and, at the age of 15, won a scholarship to the University of St Andrews. His family had been too poor to send him to university and he had been persuaded to sit the St Andrews entrance exam by his maths teacher at Beath. Until 1967, University College, Dundee was the site for all clinical medical activity for the University of St Andrews. He matriculated at University College (which eventually became the University of Dundee) in 1943 and graduated from University of St Andrews School of Medicine with an MB ChB in 1946. After graduating, he stayed at University College to join the physiology department as an assistant lecturer before taking a lecturer position at King Edward VII College of Medicine in Singapore that later became part of the University of Malaya. Black had decided against a career as a medical practitioner as he objected to what he considered the insensitive treatment of patients at the time.
Career Black had large debts upon his graduation from university, so he took a teaching job in Singapore for three years, before moving to London in 1950 and then on to join the University of Glasgow (Veterinary School) where he established the Veterinary Physiology Department and developed an interest in the way adrenaline affects the human heart, particularly in those suffering from angina. Having formulated a theory of an approach by which the effects of adrenaline might be annulled, he joined ICI Pharmaceuticals in 1958, remaining with the company until 1964, during which time he invented propranolol, which later became the world's best-selling drug. During this time Black pioneered a method of research whereby drug molecules were purposefully built instead of being synthesised first and then investigated for their potential medical uses. The discovery of propranolol was hailed as the greatest breakthrough in the treatment of heart disease since the discovery of digitalis. At the same time, Black was developing a similar method of inventing drugs for treatment of stomach ulcers, but ICI did not wish to pursue the idea so Black resigned in 1964 and joined Smith, Kline and French where he worked for nine years until 1973. While there, Black developed his second major drug, cimetidine, which was launched under the brand name Tagamet in 1975 and soon outsold propranolol to become the world's largest-selling prescription drug. Black was appointed professor, and head of department, of pharmacology at University College London in 1973 where he established a new undergraduate course in medicinal chemistry but he became frustrated by the lack of funding for research and accepted the post of director of therapeutic research at the Wellcome Research Laboratories in 1978. However he did not agree with his immediate boss there, Sir John Vane, and resigned in 1984. Black then became Professor of Analytical Pharmacology at the Rayne Institute of King's College London medical school, where he remained until 1992. He established the James Black Foundation in 1988 with funding from Johnson & Johnson and led a team of 25 scientists in drugs research, including work on gastrin inhibitors which can prevent some stomach cancers. Black contributed to basic scientific and clinical knowledge in cardiology, both as a physician and as a basic scientist. His invention of propranolol, the beta adrenergic receptor antagonist that revolutionised the medical management of angina pectoris, is considered to be one of the most important contributions to clinical medicine and pharmacology of the 20th century. Propranolol has been described as the greatest breakthrough in heart disease treatments since the 18th century discovery of digitalis and has benefited millions of people. Black's method of research, his discoveries about adrenergic pharmacology, and his clarification of the mechanisms of cardiac action are all strengths of his work. He was greatly involved in the synthesis of cimetidine, at the time a revolutionary drug for the treatment and prevention of peptic ulcers. Cimetidine was the first of a new class of drugs, the H2-receptor antagonists.
… excerpt ends here. Continue reading the full article.
